Abbreviated DAPT found safe in high-risk patients undergoing PCI
In patients at high risk of bleeding who are undergoing percutaneous coronary intervention (PCI), abbreviated dual antiplatelet therapy (DAPT) durations, especially 3-month regimens, reduces bleeding events without increasing the risk of fatal or nonfatal ischaemic cardiovascular or cerebrovascular events when compared with standard DAPT durations, according to a meta-analysis.
